Premium
Significance of Proximal Tubular Metabolism of Advanced Glycation End Products in Kidney Diseases
Author(s) -
SAITO AKIHIKO,
TAKEDA TETSURO,
SATO KIYOKO,
HAMA HITOMI,
TANUMA ATSUHITO,
KASEDA RYOHEI,
SUZUKI YOSHIKI,
GEJYO FUMITAKE
Publication year - 2005
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1333.072
Subject(s) - glycation , diabetic nephropathy , endocrinology , medicine , chemistry , metabolism , kidney , diabetes mellitus , pathogenesis , dialysis , nephropathy , receptor , rage (emotion) , amyloidosis , biology , neuroscience
A bstract : Advanced glycation end products (AGEs) are formed by the nonenzymatic Maillard reaction between sugars and proteins. Low‐molecular weight AGEs are filtered by renal glomeruli and then reabsorbed and metabolized by proximal tubule cells (PTCs). High‐molecular weight AGEs are also delivered to PTCs in proteinuric states. In patients with diabetes, AGE generation is increased, and the actions of AGEs on PTCs are likely involved in the pathogenesis of diabetic nephropathy. In patients with chronic renal failure (CRF), reduced renal metabolism of AGEs likely accounts for the accumulation of AGEs in serum, leading to uremic complications including dialysis‐related amyloidosis. AGE precursors such as reactive carbonyl compounds also accumulate in the sera of patients with CRF. It is likely that PTCs take up AGEs and AGE precursors via specific endocytotic receptors or transporters. Megalin is a multiligand endocytotic receptor that is abundantly expressed on PTCs. There is evidence that megalin is involved in the cellular uptake and degradation of AGEs. We previously reported a cell therapy model involving implantation of megalin‐expressing cells into experimental mice with renal failure for elimination of uremic toxin proteins. Further studies are needed to clarify the molecular mechanisms of the metabolism of AGEs and their precursors to develop a strategy for the treatment of diabetic nephropathy and uremic complications of CRF.